EVALUATION OF THROMBOLYTIC ACTIVITY OF DIFFERENT MARKETED POLYHERBAL FORMULATIONS

Thrombosis remains a leading cause of cardiovascular morbidity and death, with complications including myocardial infarction and stroke. It is characterized by the development of thrombi, or blood clots, inside blood vessels. Herbal remedies are increasingly being studied as safer, complementary alternatives to conventional thrombolytics like streptokinase. A human blood clot lysis model was used to investigate the in-vitro thrombolytic efficacy of two Bangladeshi polyherbal formulations, Rohitakarishta (Hepatolin) and Sharbat Chylosin (Hepa-10). Ten healthy people’s venous blood samples were placed under incubation at 37°C to cause clot formation. Thrombolytic activity of the formulations was evaluated at 100 µL and 200 µL concentrations using distilled water as the negative control and streptokinase as the positive control. The standard, streptokinase, showed maximum clot lysis (58.52% ± 2.02), while the negative control caused minimal clot lysis (2.8% ± 0.48). At 200 µL, Hepatolin caused the most clot lysis (51.52% ± 0.43), followed by Hepa-10 (42.30% ± 1.64). At 100 µL, the lysis rates of Hepatolin and Hepa-10 were (26.11% ± 2.09) and (24.36% ± 1.93), respectively. According to these findings, Hepatolin has a significant thrombolytic effect at higher dosages that is comparable to standard treatment. Even though these first findings are promising for treating thromboembolic disorders, additional in-vivo studies and phytochemical characterization are needed to clarify the underlying processes and maximize therapeutic effectiveness.